INmune Bio, Inc.
NASDAQ Capital Market•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.Company Description
- CEO
- Dr. Raymond Joseph Tesi M.D.
- Full Time Employees
- 11
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 225 NE Mizner Boulevard Boca Raton FL United States of America 33432
- IPO Date
- Feb 4, 2019
- CIK
- 0001711754
- Website
- inmunebio.com
- Similar Companies
- Business
- INmune Bio, Inc., a clinical-stage immunotherapy company, focuses on developing drugs to reprogram the patient's innate immune system to treat disease. The company develops and commercializes product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. Its development programs include INKmune, which focuses on treating women with relapse refractory ovarian carcinoma and patients with high-risk myelodysplastic syndrome; INB03, an immunotherapy that treats patients with hematologic malignancies and solid tumors; and XPro1595 for the treatment of Alzheimer's disease. The company has license agreements with Xencor, Inc.; Immune Ventures, LLC; University of Pittsburg; and University College London. INmune Bio, Inc. was incorporated in 2015 and is headquartered in Boca Raton, Florida.
Company News
INmune Bio Opens Phase II in High Dose Cohort of INKmune™ Trial in Prostate Cancer
INmune Bio Announces Plan to Submit FDA Biologics License Application (BLA) Seeking Approval of CORDStrom for Treatment of Recessive Dystrophic Epidermolysis Bullosa (RDEB)
INmune Bio: Phase 2 Trial In Alzheimer's Disease Is My Highest Risk-Reward Bet Of 2025
INmune Bio: XPro Cognitive Readout In Sight, But Mind The Financial Dangers
OmniScience Inc. and INmune Bio Inc. Partner to Accelerate a Phase 2 Alzheimer's Trial with Vivo, a Novel genAI Clinical Trial Control Tower
INmune Bio, Inc. (INMB) Q3 2024 Earnings Call Transcript
INmune Bio Inc. Announces Third Quarter 2024 Results and Provides Business Update
INmune Bio Inc. to Host Webinar on Cognitive Testing Using EMACC and CDR-SB
INmune Bio Inc. Announces Publication in Cell Reports Demonstrating XPro™ Promotes Remyelination
INmune Bio Inc. to Report Third Quarter 2024 Financial Results and Provide Corporate Update on October 31, 2024
INmune Bio Inc. to Participate in the Maxim Healthcare Virtual Summit
INmune Bio: NK Cell Therapy INKmune For mCRPC Is Another Shot On Goal
INKmune™ Demonstrates Excellent Safety and Increased NK-Cell Activity in First Dosing Cohort
INmune Bio Announces Results of Additional Blinded Interim Analysis of Phase 2 Alzheimer's Disease Trial Demonstrating Correlation between EMACC and CDR-SB Endpoints
INmune Bio Announces $13.0 Million Registered Direct Offering
INmune Bio Inc. to Present at the Baird 2024 Global Healthcare Conference
INmune Bio, Inc. (INMB) Q2 2024 Earnings Call Transcript
INmune Bio Inc. Announces Second Quarter 2024 Results and Provides Business Update
INmune Bio Inc. Announces New Phase 1 Study Data Demonstrating Dose-Dependent Effect of XPro™ on Proteins that Regulation Synapses in Alzheimer's Patients
INmune Bio Inc. to Report Second Quarter 2024 Financial Results and Provide a Corporate Update on Thursday, August 1, 2024